Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the efficacy of high throughput genome analysis as a therapeutic decision tool for patients with metastatic breast cancer

Next Previous
Search
Trial Profile

Evaluation of the efficacy of high throughput genome analysis as a therapeutic decision tool for patients with metastatic breast cancer

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABSK 091 (Primary) ; Bicalutamide (Primary) ; Capivasertib (Primary) ; Durvalumab (Primary) ; Olaparib (Primary) ; Sapitinib (Primary) ; Selumetinib (Primary) ; Vandetanib (Primary) ; Vistusertib (Primary) ; Bevacizumab; Capecitabine; Carboplatin; Cisplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Doxorubicin liposomal; Epirubicin; Eribulin; Fluorouracil; Gemcitabine; Methotrexate; Mitomycin; Paclitaxel; Vinblastine; Vincristine; Vinorelbine
  • Indications Advanced breast cancer; Cancer metastases; Male breast cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms SAFIR 02 Breast

    • Most Recent Events

    • 15 Jan 2025 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
    • 09 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
    • 03 Feb 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top